Sep 9, 2026
Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a...
Sep 9, 2026
Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a...
Jul 13, 2026
Lisa Gurry, Chief Business Officer at GeneDx, is transforming the diagnosis of rare diseases in children by providing comprehensive genetic testing. Using exome and genome sequencing, they deliver rapid, accurate results that enable early intervention and access to therapies. Through partnerships and a network of...
Jul 13, 2026
Lisa Gurry, Chief Business Officer at GeneDx, is transforming the diagnosis of rare diseases in children by providing comprehensive genetic testing. Using exome and genome sequencing, they deliver rapid, accurate results that enable early intervention and access to therapies. Through partnerships and a network of...
Jun 29, 2026
Sten Sörensen, CEO of Cereno Scientific, discusses work on epigenetic modulation to treat the rare disease Pulmonary Arterial Hypertension, a progressive and fatal condition for which current treatments primarily manage symptoms. Core pathological processes of PAH include inflammation, fibrosis, and the growth of...